Insiders who reported open-market trades in the last 12 months at the companies Nancy Thornberry files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Alexander O. Schuth - $137K in DNLI purchases and sales in the last 12 months
Peter Scott Chin - $37K in DNLI purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Nancy Thornberry is a corporate insider, tracked as Director of Denali Therapeutics Inc. (DNLI). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Nancy Thornberry submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Nancy Thornberry been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($262K) across all tracked filings.
Nancy Thornberry is Director of Denali Therapeutics Inc. (DNLI). 4 SEC Form 4 filings on record, most recently on 4 September 2026. Most recent open-market trade: sold $15K of DNLI on 4 September 2026. Lifetime open-market sales: $262K.
Recent transactions
6
The latest 6 SEC Form 4 transactions reported by Nancy Thornberry.
InsiderAlpha's records for Nancy Thornberry go back to 2026: 4 primary Form 4 filings, an average of 4.0 per year. 2 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
